XLO · Xilio Therapeutics Inc
United States · RS rating 54 · As of 2026-11-03
| Price | 8.68 USD |
|---|---|
| 1-day change | +8.6% |
| RS rating (overall / 1M / 3M / 12M) | 54 / 45 / 56 / 35 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 32 / 14 / 58 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +836.4% |
| Sales growth Q/Q | -28.2% |
| Distance from 52-week high | +27.1% |
| Market cap (USD) | $49.0M |